Article info

Original research
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

Authors

  1. Correspondence to Dr Caicun Zhou; caicunzhou_dr{at}163.com; Dr Jia Fan; fan.jia{at}zs-hospital.sh.cn
View Full Text

Citation

Ren S, Wang X, Han B, et al
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

Publication history

  • Accepted January 29, 2024
  • First published February 21, 2024.
Online issue publication 
February 21, 2024
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.